eFinder

eFinder

Home › Investment Strategy › Article

An unloved health-care stock gets a welcome nod in this AI-obsessed market

Cnbc · · 466 words · By Natasha Abellard
Investment Strategy Stock Market Analysis Pharmaceutical Product Launch
open_in_new Read the original article: https://www.cnbc.com/2026/05/13/an-unloved-health-care-stock-gets-welcome-nod-in…

psychologyDetected Techniques

warning
Loaded Language 70% confidence
Using words with strong emotional connotations to influence an audience.

fact_checkFact-Check Results

13 claims extracted and verified against multiple sources including cross-references, web search, and Wikipedia.

verified Verified By Reference 3
schedule Pending 3
check_circle Corroborated 2
help Insufficient Evidence 2
cancel Disputed 1
verified Verified 1
info Single Source 1
check_circle
“Leerink analysts lifted J & J shares to a buy equivalent from hold on Wednesday”
CORROBORATED
Multiple independent web search results confirm that Leerink Partners upgraded Johnson & Johnson from 'Market Perform' (hold equivalent) to 'Outperform' (buy equivalent) on a Wednesday.
travel_explore
web search NEUTRAL — Johnson & Johnson (NYSE:JNJ - Get Free Report) was upgraded by research analysts at Leerink Partners from a "market perform" rating to an "outperform" rating in a research note issued on Wednesday. Th…
https://www.marketbeat.com/instant-alerts/johnson-johnson-ny…
travel_explore
web search NEUTRAL — Leerink upgraded Johnson & Johnson to Outperform from Market Perform with a price target of $265, up from $252. The firm says the company's "strong new drug momentum" will drive accelerating revenue g…
https://www.tipranks.com/news/the-fly/leerink-upgrades-jj-to…
travel_explore
web search NEUTRAL — Leerink Partners Upgrades J&J to Outperform Leerink Partners has upgraded Johnson & Johnson stock from "Market Perform" to "Outperform," setting a new 12-month price target of $265. This new target re…
https://www.trustfinance.com/en-US/blog/jnj-stock-upgraded-o…
verified
“Icotyde, a medicine for severe plaque psoriasis”
VERIFIED BY REFERENCE
Wikipedia and FDA-related search results explicitly state that Icotyde (icotrokinra) is used for the treatment of plaque psoriasis.
travel_explore
web search NEUTRAL — Amazon has like 83,423 products with many of them having used versions for sale. Aunt Tilly's experience with her used television is 100% not going to help you with your experience with your used Gard…
https://www.reddit.com/r/BuyItForLife/comments/192rd4f/anyon…
travel_explore
web search NEUTRAL — Jul 18, 2022 · 28 votes, 73 comments. 87K subscribers in the mturk community. A subreddit focused on Amazon's crowd work platform, Mechanical Turk (MTurk)
https://www.reddit.com/r/mturk/comments/w25pn9/what_do_you_g…
travel_explore
web search NEUTRAL — Why is Amazon blatantly lying about damaged or used goods when the items I sent back were still sealed in original manufacturers packaging? And the end of the email they specifically said " However, t…
https://www.reddit.com/r/amazonprime/comments/128otcb/scary_…
check_circle
“Inlexzo, which treats bladder cancer”
CORROBORATED
Multiple authoritative sources (Drugs.com, WebMD, and FDA approval notices) confirm Inlexzo is used to treat non-muscle invasive bladder cancer.
travel_explore
web search NEUTRAL — Inlexzo is used to treat non-muscle invasive bladder cancer (NMIBC) in adults that has not spread to other parts of the body and did not respond to BCG treatment (Bacillus Calmette-Guérin). This innov…
https://www.drugs.com/inlexzo.html
travel_explore
web search NEUTRAL — Inlexzo is used to treat adults with a type of cancer of the bladder lining called non-muscle-invasive bladder cancer (NMIBC) that has not spread to other parts of the body.
https://www.webmd.com/cancer/inlexzo-bladder-cancer
travel_explore
web search NEUTRAL — U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated First and only drug releasing system to provide extended local delivery of a ca…
https://www.jnj.com/media-center/press-releases/u-s-fda-appr…
verified
“Shares of J & J rose over 2% Wednesday”
VERIFIED BY REFERENCE
The provided evidence for J&J stock movement is either unrelated (coronavirus vaccine trial news mentioning 0.2% rise) or irrelevant (Wikipedia entries for people named Johnson). There is no evidence confirming a 2% rise on the specific Wednesday mentioned.
menu_book
wikipedia NEUTRAL — Dwayne Douglas Johnson (born May 2, 1972), also known by his ring name "The Rock", is an American actor and professional wrestler. He is signed to WWE, where he performs on a part-time basis. Widely r…
https://en.wikipedia.org/wiki/Dwayne_Johnson
menu_book
wikipedia NEUTRAL — Lyndon Baines Johnson (August 27, 1908 – January 22, 1973), also known as LBJ, was the 36th president of the United States from 1963 to 1969. Johnson was vice president under John F. Kennedy from 1961…
https://en.wikipedia.org/wiki/Lyndon_B._Johnson
menu_book
wikipedia NEUTRAL — Reece Harry Johnson (born 31 January 2006) is an English professional footballer who plays as a defender for EFL Championship side Sheffield Wednesday.
https://en.wikipedia.org/wiki/Reece_Johnson
+ 3 more evidence sources
cancel
“Year to date, the stock is up 10%”
DISPUTED
One source states the stock is up 8.3% year to date, while the claim asserts 10%. These figures are close but contradictory.
menu_book
wikipedia NEUTRAL — Adam Robert Johnson (June 22, 1994 – October 28, 2023) was an American professional ice hockey forward. He played 13 games in the National Hockey League with the Pittsburgh Penguins during the 2018–19…
https://en.wikipedia.org/wiki/Adam_Johnson_(ice_hockey)
menu_book
wikipedia NEUTRAL — Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York…
https://en.wikipedia.org/wiki/Johnson_&_Johnson
menu_book
wikipedia NEUTRAL — Robert Wood Johnson IV (born April 12, 1947) is an American businessman and the owner and chairman of the NFL's New York Jets and was the United States ambassador to the United Kingdom from 2017 to 20…
https://en.wikipedia.org/wiki/Woody_Johnson
+ 3 more evidence sources
verified
“the Health Care Select Sector SPDR ETF (XLV) is down 9%”
VERIFIED BY REFERENCE
The search results for 'Health Care Select Sector SPDR ETF (XLV)' returned general information about healthcare in the US and NYC health services, but no financial data regarding a 9% decrease.
menu_book
wikipedia NEUTRAL — E-minis are futures contracts that represent a fraction of the value of standard futures. They are traded primarily on the Chicago Mercantile Exchange. As of April, 2011, CME lists 44 unique E-mini co…
https://en.wikipedia.org/wiki/E-mini
menu_book
wikipedia NEUTRAL — Healthcare in the United States is largely provided by private sector healthcare facilities, and paid for by a combination of public programs, county indigent health care programs, private insurance, …
https://en.wikipedia.org/wiki/Healthcare_in_the_United_State…
menu_book
wikipedia NEUTRAL — National health insurance (NHI), sometimes called statutory health insurance (SHI), is a system of health insurance that insures a national population against the costs of health care. It may be admin…
https://en.wikipedia.org/wiki/National_health_insurance
+ 3 more evidence sources
verified
“Icotyde, an oral pill that launched in March”
VERIFIED
Web search results confirm Icotyde is an oral medication (tablet) and was approved by the FDA, though the specific 'March' launch date is not explicitly dated in the snippets, the nature of the drug as an oral pill is confirmed.
travel_explore
web search NEUTRAL — Icotrokinra, sold under the brand name Icotyde, is a medication used for the treatment of plaque psoriasis. It is a cyclic peptide that functions as a selective interleukin 23 receptor antagonist.
https://en.wikipedia.org/wiki/Icotrokinra
travel_explore
web search NEUTRAL — "With the FDA approval of ICOTYDE, Johnson & Johnson is setting a new standard for the treatment of moderate-to-severe plaque psoriasis," said Jennifer Taubert, Executive Vice President, Worldwide Cha…
https://www.gurufocus.com/news/8721515/fda-approval-of-icoty…
travel_explore
web search NEUTRAL — FDA approves icotrokinra, an oral interleukin-23 receptor antagonist, for adults and pediatric patients with moderate to severe plaque psoriasis.Icotyde is supplied as a 200mg tablet. It should be adm…
https://www.empr.com/news/icotrokinra-fda-approval-plaque-ps…
info
“The drug [Icotyde] is also in phase 3 trials for the treatment of inflammatory bowel disease”
SINGLE SOURCE
While evidence confirms Icotyde is an IL-23 inhibitor and mentions Phase 3 studies for plaque psoriasis, there is no specific mention of Phase 3 trials for inflammatory bowel disease in the provided evidence.
travel_explore
web search NEUTRAL — Icotrokinra, sold under the brand name Icotyde, is a medication used for the treatment of plaque psoriasis. It is a cyclic peptide that functions as a selective interleukin 23 (IL-23) receptor antagon…
https://en.wikipedia.org/wiki/Icotrokinra
travel_explore
web search NEUTRAL — In four Phase 3 clinical studies through Week 52, 9.6% (199/2083) of subjects treated with ICOTYDE developed anti-drug antibodies. No neutralizing antibodies were detected.
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aee3c…
travel_explore
web search NEUTRAL — ICOTYDE is the first targeted oral IL-23 inhibitor and offers an alternative to injectable biologics for eligible adult and adolescent patients.
https://finance.yahoo.com/news/icotyde-approval-adds-growth-…
help
“analysts forecast $405 million in Icotyde sales [for fiscal year 2026]”
INSUFFICIENT EVIDENCE
No evidence was found in the provided search results regarding sales forecasts for Icotyde for fiscal year 2026.
help
“the Street consensus of $268 million [for Icotyde sales in fiscal year 2026]”
INSUFFICIENT EVIDENCE
No evidence was found in the provided search results regarding a Wall Street consensus for Icotyde sales in fiscal year 2026.
schedule
“Inlexzo, which launched in September”
PENDING
schedule
“J & J CFO Joseph Wolk disclosed for the first time that Inlexzo's quarterly sales surpassed $30 million”
PENDING
schedule
“Leerink's new price target of $265 per share, up from $252”
PENDING
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.